Value of fluorodeoxyglucose positron emission tomography in characterizing clinically-significant thyroid carcinomas

Surgical Practice

Volumn 15, Issue 2, 2011, Pages 34-40

  Chan, Desmond Kwan Kit ^a   Lang, Brian Hung Hin ^a   Law, Tsz Ting ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Fluorodeoxyglucose; Positron emission tomography; Thyroid carcinoma; Thyroid incidentaloma; Thyroid neoplasm

Indexed keywords

EID: 79955040214     PISSN: 17441625     EISSN: 17441633     Source Type: Journal    
DOI: 10.1111/j.1744-1633.2011.00538.x     Document Type: Article

References (31)

1. Mazzaferri EL, Gerfo PL, Mallette LE etal. Management of a solitary thyroid nodule. N. Engl. J. Med. 1993; 329: 360-1.
2. Kang KW, Kim SK, Kang HS etal. Prevalence and risk of cancer of focal thyroid incidentalomas identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J. Clin. Endocrinol. Metab. 2003; 88: 4100-4.
3. Jin J, Wilhelm SM, McHenry CR. Incidental thyroid nodule: patterns of diagnosis and rate of malignancy. Am. J. Surg. 2009; 197: 320-4.
4. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 292: 2632-42.
5. Burguera B, Garib H. Thyroid incidentalomas: prevalence, diagnosis, significance, and management. Endocrinol. Metab. Clin. North Am. 2000; 29: 187-203.
6. Gough J, Scott-Coombes D, Palazzo FF. Thyroid incidentaloma: an evidence-based assessment of management strategy. World J. Surg. 2008; 32: 1264-8.
7. Ito Y, Miyauchi A, Inoue H etal. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J. Surg. 2010; 34 (1): 28-35.
8. Lo CY, Chan WF, Lang BH etal. Papillary microcarcinoma: is there any difference between clinically overt and occult tumors? World J. Surg. 2006; 30: 759-66.
9. Mortensen JD, Woolner LB, Bennett WA. Gross and microscopic findings in clinically normal thyroid glands. J. Clin. Endocrinol. Metab. 1955; 15: 1270-80.
10. Nam-Goong IL, Kim HY, Gong G etal. Ultrasonographically-guided fine needle aspirations of thyroid incidentaloma: correlation with pathologic findings. Clin. Endocrinol. (Oxf). 2004; 60: 21-8.
11. Kim DL, Song KH, Kim SK. High prevalence of carcinoma in ultrasonography-guided fine needle aspiration cytology of thyroid nodules. Endocr. J. 2008; 55: 135-42.
12. Wilhelm SM, Robinson AV, Krishnamurthi SS etal. Evaluation and management of incidental thyroid nodules in patients with another primary malignancy. Surgery 2007; 142: 581-7.
13. Law TT, Lang BH. Incidental thyroid carcinoma by FDG-PET/CT - a study of clinico-pathological characteristics. Ann. Surg. Oncol. 2011; 18: 472-8.
14. Are C, Hsu JF, Ghossein RA etal. Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas. Ann. Surg. Oncol. 2007; 14: 3210-15.
15. Rivera M, Ghossein RA, Schoder H etal. Histological characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 2008; 113: 48-56.
16. Robbins RJ, Wan Q, Grewal RK etal. Real-time prognosis for metastatic thyroid carcinoma based on 2-(18F)-fluoro-2-deoxy-D-gluocse positron emission tomography scanning. J. Clin. Endocrinol. Metab. 2006; 91: 498-505.
17. Moon WJ, Jung SL, Lee JH etal. Benign and malignant thyroid nodules: US differentiation - multicenter retrospective study. Radiology 2009; 247: 762-70.
18. Cooper DS, Doherty GM, Haugen BR etal. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-214.
19. Hong Kong Cancer Registry, Hong Kong. Cancer incidence and mortality in Hong Kong 1983-2007. 2010. [Cited 2 Feb 2010.] Available from URL:
20. Welch HG, Black WC. Overdiagnosis in cancer. J. Natl. Cancer Inst. 2010; 102: 605-13.
21. Traugott AL, Dehdashti F, Trinkaus K etal. Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18F-fluorodeoxyglucose positron emission tomography: interim analysis. World J. Surg. 2010; 34: 1247-53.
22. 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl. Med. Commun. 2007; 28: 373-81.
23. 18F-Fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer. Res. 2005; 25: 1421-6.
24. Kim JM, Ryu J-S, Kim TY etal. 18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J. Clin. Endocrinol. Metab. 2007; 92: 1630-4.
25. Nam SY, Roh J-L, Kim JS etal. Focal uptake of (18)F-fluorodeoxyglucose by thyroid in patients with nonthyroidal head and neck cancers. Clin. Endocrinol. (Oxf). 2007; 67: 135-9.
26. Kresnik E, Gallowitsch HJ, Mikosch P etal. Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery 2003; 133: 294-9.
27. Are C, Hsu JF, Schoder H etal. FDG-PET detected thyroid incidentalomas: need for further investigation? Ann. Surg. Oncol. 2007; 14: 239-47.
28. Salvatori M, Melis L, Castaldi P etal. Clinical significance of focal and diffuse thyroid diseases identified by (18)F-fluorodeoxyglucose positron emission tomography. Biomed. Pharmacother. 2007; 61: 488-93.
29. Yasuda S, Shohtsu A, Ide M etal. Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology 1998; 107: 775-8.
30. Lang BH, Law TT. The role of 18F-fluorodeoxyglucose Positron Emission Tomography in thyroid neoplasms. Oncologist. doi: 10.1634/theoncologist.2010-0256
31. Schmid DT, Kneifel S, Stoeckli SJ etal. Increased 18F-FDG uptake mimicking thyroid cancer in a patient with Hashimoto's thyroiditis. Eur. Radiol. 2003; 13: 2119-21.